anti-GARP CAR T cell therapy
/ The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James)
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 30, 2025
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Ohio State University Comprehensive Cancer Center | Not yet recruiting ➔ Recruiting
Enrollment open • Anaplastic Astrocytoma • Brain Cancer • Glioblastoma • Glioma • Malignant Glioma • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1